Interim Position Statement: Inhaled budesonide for adults (50 years and over) with COVID-19

Based on interim results of PRINCIPLE trial which shows that inhaled budesonide can reduce recovery time for COVID-19 positive patients, it can now be prescribed off-label by healthcare professionals on a case-by-case basis using the information described in this Statement.

SPS commentary:

The guidance notes that as per trial entry criteria, this is for initiation in the community setting only and that patients admitted to hospital with COVID-19 before onset of treatment with budesonide are to be excluded.


Medicines and Healthcare products Regulatory Agency